Shots:
An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies
In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com
Established in 1993 in San Francisco, California,…
Shots:
The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B
In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

